Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Frank Bennett

Showing results (91-100 of 169) with videos related to

Pageof 17
Sort By:
Science Translational Medicine|April 22, 2026
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of <i>HNRNPH2</i>-related neurodevelopmental disorderAne Korff, Xiaojing Yang, Ozan Ozdemir, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2017
SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damageMohini Jangi, Christina Fleet, Patrick Cullen, et al.
Brain : a Journal of Neurology|July 3, 2018
CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosisEva Janzen, Natalia Mendoza-Ferreira, Seyyedmohsen Hosseinibarkooie, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of <i>HNRNPH2</i>-related neurodevelopmental disorderAne Korff, Xiaojing Yang, Ozan Ozdemir, et al.
Science Advances|August 22, 2025
An alternative cytoplasmic SFPQ isoform with reduced phase separation potential is up-regulated in ALSJacob Neeves, Marija Petrić Howe, Oliver J Ziff, et al.
Nature Neuroscience|June 4, 2021
Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTBRoy Maimon, Carlos Chillon-Marinas, Cedric E Snethlage, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2014
Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primatesFrank Rigo, Seung J Chun, Daniel A Norris, et al.
Journal of Medicinal Chemistry|April 14, 2006
Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acidsMartin A Maier, Christine C Esau, Andrew M Siwkowski, et al.
Nucleic Acids Research|December 4, 2020
High-resolution visualization and quantification of nucleic acid-based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS)Cuiwen He, Michael T Migawa, Kai Chen, et al.
Neuron|December 27, 2016
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular AtrophyConstantin d'Ydewalle, Daniel M Ramos, Noah J Pyles, et al.
Pageof 17

Showing results (91-100 of 169) with videos related to

Sort By:
Pageof 17
Science Translational Medicine|April 22, 2026
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of <i>HNRNPH2</i>-related neurodevelopmental disorderAne Korff, Xiaojing Yang, Ozan Ozdemir, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 9, 2017
SMN deficiency in severe models of spinal muscular atrophy causes widespread intron retention and DNA damageMohini Jangi, Christina Fleet, Patrick Cullen, et al.
Brain : a Journal of Neurology|July 3, 2018
CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosisEva Janzen, Natalia Mendoza-Ferreira, Seyyedmohsen Hosseinibarkooie, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
Preclinical evaluation of antisense oligonucleotide therapy in a mouse model of <i>HNRNPH2</i>-related neurodevelopmental disorderAne Korff, Xiaojing Yang, Ozan Ozdemir, et al.
Science Advances|August 22, 2025
An alternative cytoplasmic SFPQ isoform with reduced phase separation potential is up-regulated in ALSJacob Neeves, Marija Petrić Howe, Oliver J Ziff, et al.
Nature Neuroscience|June 4, 2021
Therapeutically viable generation of neurons with antisense oligonucleotide suppression of PTBRoy Maimon, Carlos Chillon-Marinas, Cedric E Snethlage, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 3, 2014
Pharmacology of a central nervous system delivered 2'-O-methoxyethyl-modified survival of motor neuron splicing oligonucleotide in mice and nonhuman primatesFrank Rigo, Seung J Chun, Daniel A Norris, et al.
Journal of Medicinal Chemistry|April 14, 2006
Evaluation of basic amphipathic peptides for cellular delivery of antisense peptide nucleic acidsMartin A Maier, Christine C Esau, Andrew M Siwkowski, et al.
Nucleic Acids Research|December 4, 2020
High-resolution visualization and quantification of nucleic acid-based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS)Cuiwen He, Michael T Migawa, Kai Chen, et al.
Neuron|December 27, 2016
The Antisense Transcript SMN-AS1 Regulates SMN Expression and Is a Novel Therapeutic Target for Spinal Muscular AtrophyConstantin d'Ydewalle, Daniel M Ramos, Noah J Pyles, et al.
Pageof 17